Spinal Restoration has received a notice of allowance (NOA) from the US Patent and Trademark Office (USPTO) for the claims regarding delivery device and method of use of the Biostat System for the treatment of discogenic low back pain.
Claims are directed towards the Biostat System which comprises of Biostat Biologx Fibrin Sealant, a human derived, biologic tissue sealant, and the Biostat Delivery Device, an application system designed for safe delivery of biologic materials to the intervertebral disc.
Spinal Restoration president and CEO Gary Sabins said the allowance of these claims strengthens the company’s intellectual property portfolio and helps to fortify their position in the field of intradiscal biologic therapies.